Bad versions of a cancer drug are putting child patients at risk. Why is it still on the market?

Your browser doesn’t support HTML5 audio

Here & Now‘s Peter O’Dowd talks with reporter Rosa Furneaux about how an ineffective version of a drug that treats a specific type of leukemia remains on the market, affecting tens of thousands of child patients around the world.

This article was originally published on WBUR.org.

Copyright 2023 NPR. To see more, visit https://www.npr.org.

  • Facebook
  • Twitter
  • LinkedIn
  • Email